Comparing Oral Versus Parenteral Antimicrobial Therapy — COPAT  

Bone and Joint Infection Clinical Trial

Official title: Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial

Status Enrolling by invitation

Clinical Trial Summary

This is an investigator initiated multisite pragmatic randomized controlled trial designed to demonstrate equivalent effectiveness with improved safety of early transition from intravenous (IV) antimicrobial therapy to complex outpatient oral antimicrobial therapy (COpAT) across various infectious diseases (endovascular, bone and joint, skin and soft tissue, pulmonary, gastrointestinal, and genitourinary infections). All patients referred for outpatient parenteral antimicrobial therapy (OPAT) will be evaluated by the research team with respect to inclusion/exclusion criteria. If determined eligible for enrollment, patients will be approached by a study investigator who will present the COPAT Trial. Once informed consent is obtained, patients will be randomized 2:1 using computer software into experimental or control (standard of care) group, respectively: Experimental: COpAT only on hospital discharge; Control: Conventional OPAT, OPAT transitioned to COpAT later in outpatient setting, or long-acting parenteral lipoglycopeptides. Both groups will be followed by an ID physician on the research team with in-person or telemedicine ID Clinic standard of care visits at 2, 6, and 12 weeks after hospital discharge. At the 6-week ID Clinic follow-up, patients will be asked to complete a patient satisfaction survey. The following 2 primary outcomes will be assessed: cure at 3 months using clinical (resolution of infection) and laboratory parameters (improvement in inflammatory markers) and adverse events related to antimicrobial therapy/vascular access complication. The following 3 secondary outcomes will be assessed: overall readmission at 3 months, readmission related to initial infection or antimicrobial therapy/vascular access complication at 3 months, and patient satisfaction at 6 weeks. The experimental group is being compared to standard of care in current clinical practice. As this is a pragmatic clinical trial, patients will not undergo additional invasive testing or procedures.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Bone and Joint Infection
• Communicable Diseases
• Gastrointestinal Infection
• Infections
• Pulmonary Infection
• Skin and Soft Tissue Infection
• Soft Tissue Infections

• NCT number: NCT05977868
• Study type: Interventional
• Source: West Virginia University
• Status: Enrolling by invitation
• Phase: Phase 4
• Start date: August 4, 2023
• Completion date: August 2024